المؤلفون: Antonarakis, ES, Piulats, JM, Gross-Goupil, M, Goh, J, Ojamaa, K, Hoimes, CJ, Vaishampayan, U, Berger, R, Sezer, A, Alanko, T, de Wit, R, Li, CD, Omlin, A, Procopio, G, Fukasawa, S, Tabata, KI, Park, SH, Feyerabend, S, Drake, CG, Wu, HY, Qiu, P, Kim, J, Poehlein, C, de Bono, JS

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(5):395-405

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:143312962

المؤلفون: Antonarakis, ES, Piulats, JM, Gross-Goupil, M, Goh, JC, Vaishampayan, UN, De Wit, R, Alanko, TV, Fukasawa, S, Tabata, K, Feyerabend, S, Berger, R, Ojamaa, K, Hoimes, CJ, Sezer, A, Omlin, AG, Yachnin, J, Niu, C, Poehlein, CH, Schloss, C, de Bono, JS

المصدر: ANNALS OF ONCOLOGY. 32:S651-S652

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:147790274

المؤلفون: Merl, MY, Hoimes, CJ, Pham, T, Saif, M Wasif

المصدر: Expert Opinion on Investigational Drugs; September 2009, Vol. 18 Issue: 9 p1257-1264, 8p

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Sfakianos JP; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Basu A; University of Alabama, Birmingham, AL, USA., Laliotis G; Natera Inc, Austin, TX, USA., Cumarasamy S; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Rich JM; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Kommalapati A; University of Alabama, Birmingham, AL, USA., Glover M; Stanford University Medical Center, Stanford, CA, USA., Mahmood T; Natera Inc, Austin, TX, USA., Tillu N; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Hoimes CJ; Duke University, Durham, NC, USA., Selig G; Duke University, Durham, NC, USA., Kollipara R; Rush University Medical Center, Chicago, IL, USA., Stewart TF; UC San Diego Health, La Jolla, CA, USA., Rivero-Hinojosa S; Natera Inc, Austin, TX, USA., Dutta P; Natera Inc, Austin, TX, USA., Calhoun M; Natera Inc, Austin, TX, USA., Sharma S; Natera Inc, Austin, TX, USA., Malhotra M; Natera Inc, Austin, TX, USA., ElNaggar AC; Natera Inc, Austin, TX, USA., Liu MC; Natera Inc, Austin, TX, USA., Ferguson JE 3rd; University of Alabama, Birmingham, AL, USA., Diniz M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Mehrazin R; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Wiklund P; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Tan A; Rush University Medical Center, Chicago, IL, USA., Shah S; Stanford University Medical Center, Stanford, CA, USA., Galsky MD; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: matthew.galsky@mssm.edu.

المصدر: European urology oncology [Eur Urol Oncol] 2024 Jul 15. Date of Electronic Publication: 2024 Jul 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE

المؤلفون: Msaouel P; University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: PMsaouel@mdanderson.org., Sweis RF; University of Chicago Medicine, Chicago, IL, USA., Bupathi M; Rocky Mountain Cancer Centers - Littleton, Littleton, CO, USA., Heath E; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA., Goodman OB Jr; Comprehensive Cancer Centers of Nevada - Southwest, Las Vegas, NV, USA., Hoimes CJ; Duke University Hospital, Durham, NC, USA., Milowsky MI; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Davis N; Vanderbilt - Ingram Cancer Center, Nashville, TN, USA., Kalebasty AR; University of California Irvine, Irvine, CA, USA., Picus J; Washington University School of Medicine, Siteman Cancer Center, Saint Louis, MO, USA., Shaffer D; New York Oncology Hematology - Albany Medical Center, Albany, NY, USA., Mao S; Allegheny General Hospital, Pittsburgh, PA, USA., Adra N; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA., Yorio J; Texas Oncology - Austin Central, Austin, TX, USA., Gandhi S; Florida Cancer Specialists and Research Institute - North Region (SCRI), Tampa Bay, FL, USA., Grivas P; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA., Siefker-Radtke A; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yang R; Mirati Therapeutics, Inc., San Diego, CA, USA., Latven L; Mirati Therapeutics, Inc., San Diego, CA, USA., Olson P; Mirati Therapeutics, Inc., San Diego, CA, USA., Chin CD; Mirati Therapeutics, Inc., San Diego, CA, USA., Der-Torossian H; Mirati Therapeutics, Inc., San Diego, CA, USA., Mortazavi A; Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, and the Comprehensive Cancer Center, Columbus, OH, USA., Iyer G; Memorial Sloan Kettering Cancer Center, New York, NY, USA.

المصدر: European urology oncology [Eur Urol Oncol] 2024 Aug; Vol. 7 (4), pp. 933-943. Date of Electronic Publication: 2023 Dec 16.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study

بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Nivolumab*/therapeutic use , Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/secondary , Carcinoma, Transitional Cell*/pathology , Carcinoma, Transitional Cell*/mortality , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Aged ; Male ; Female ; Middle Aged ; Aged, 80 and over ; Adult ; Neoplasm Metastasis ; Urologic Neoplasms/drug therapy ; Urologic Neoplasms/pathology ; Urologic Neoplasms/mortality ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/pathology

المؤلفون: Milowsky MI; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., O'Donnell PH; University of Chicago, Chicago, IL., Hoimes CJ; Duke Cancer Institute, Duke University, Durham, NC., Petrylak DP; Yale Cancer Center, New Haven, CT., Flaig TW; University of Colorado Comprehensive Cancer Center, Aurora, CO., Moon HH; Kaiser Permanente Southern California, Riverside, CA., Friedlander TW; University of California San Francisco Medical Center, San Francisco, CA., Mar N; University of California Irvine, Irvine, CA., McKay RR; University of California San Diego, San Diego, CA., Srinivas S; Stanford University Medical Center, Stanford, CA., Gravis G; Institut Paoli-Calmettes, Marseille, France., Ramamurthy C; MD Anderson Cancer Center, University of Texas Health, San Antonio, TX., Bupathi M; Rocky Mountain Cancer Centers, Littleton, CO., Bracarda S; Azienda Ospedaliera Santa Maria Terni, Terni, Italy., Wright P; Seagen Inc, Bothell, WA., Hepp Z; Seagen Inc, Bothell, WA., Carret AS; Seagen Inc, Bothell, WA., Yu Y; Seagen Inc, Bothell, WA., Dillon R; Astellas Pharma Inc, Northbrook, IL., Kataria R; Merck & Co, Inc, Rahway, NJ., Beaumont JL; Clinical Outcomes Solutions Ltd, Tucson, AZ., Purnajo I; Clinical Outcomes Solutions Ltd, Tucson, AZ., Rosenberg JE; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Apr 20; Vol. 42 (12), pp. 1403-1414. Date of Electronic Publication: 2024 Jan 12.

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal* , Antibodies, Monoclonal, Humanized* , Carcinoma, Transitional Cell* , Sleep Initiation and Maintenance Disorders*, Humans ; Cisplatin ; Pain ; Patient Reported Outcome Measures ; Quality of Life/psychology

المؤلفون: Hoimes CJ; Duke Cancer Institute; Duke University, Durham, NC, USA., Flaig TW; University of Colorado Comprehensive Cancer Center, Aurora, CO, USA., Milowsky MI; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA., Friedlander TW; University of California San Francisco Medical Center, San Francisco, CA, USA., Bilen MA; Winship Cancer Institute of Emory University, Hematology & Medical Oncology, Atlanta, GA, USA., Gupta S; Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Srinivas S; Stanford University Medical Center, Stanford, CA, USA., Merchan JR; University of Miami, Medical Oncology, Miami, FL, USA., McKay RR; University of California San Diego Moores Cancer Center, San Diego, CA, USA., Petrylak DP; Yale Comprehensive Cancer Center, New Haven, CT, USA., Sasse C; Astellas Pharma Global Development, Northbrook, IL, USA., Moreno BH; Merck & Co., Inc., Rahway, NJ, USA., Yu Y; Seagen Inc., Bothell, WA, USA., Carret AS; Seagen Inc., Bothell, WA, USA., Rosenberg JE; Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, NY, USA.

المصدر: Future oncology (London, England) [Future Oncol] 2024 Mar; Vol. 20 (7), pp. 351-360. Date of Electronic Publication: 2023 Nov 23.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Urologic Neoplasms*/drug therapy , Urologic Neoplasms*/pathology , Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/pathology , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology, Humans ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal/adverse effects

المؤلفون: Moore EC; Tempus Labs, Inc, Chicago, Illinois, USA., Blobe GC; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA., DeVito NC; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Center for Cancer Immunotherapy, Duke University Medical Center, Durham, North Carolina, USA., Hanks BA; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA.; Center for Cancer Immunotherapy, Duke University Medical Center, Durham, North Carolina, USA., Harrison MR; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA., Hoimes CJ; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Center for Cancer Immunotherapy, Duke University Medical Center, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA., Jia J; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA., Morse MA; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA., Jayaprakasan P; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA., MacKelfresh A; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA., Mulder H; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA., Hockenberry AJ; Tempus Labs, Inc, Chicago, Illinois, USA., Zander A; Tempus Labs, Inc, Chicago, Illinois, USA., Stumpe MC; Tempus Labs, Inc, Chicago, Illinois, USA., Michuda J; Tempus Labs, Inc, Chicago, Illinois, USA., Beauchamp KA; Tempus Labs, Inc, Chicago, Illinois, USA., Perakslis E; Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA., Taxter T; Tempus Labs, Inc, Chicago, Illinois, USA., George DJ; Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA.

المصدر: Cancer medicine [Cancer Med] 2023 Oct; Vol. 12 (19), pp. 19394-19405. Date of Electronic Publication: 2023 Sep 15.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms, Unknown Primary*/diagnosis , Neoplasms, Unknown Primary*/genetics , Neoplasms, Unknown Primary*/pathology , Neoplasms, Second Primary*, Humans ; Retrospective Studies ; Pathology, Molecular

المؤلفون: O'Donnell PH; University of Chicago, Chicago, IL., Milowsky MI; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Petrylak DP; Yale Cancer Center, New Haven, CT., Hoimes CJ; Duke Cancer Institute, Duke University, Durham, NC., Flaig TW; University of Colorado Comprehensive Cancer Center, Aurora, CO., Mar N; University of California at Irvine, Irvine, CA., Moon HH; Kaiser Permanente Southern California, Riverside, CA., Friedlander TW; University of California at San Francisco, San Francisco, CA., McKay RR; University of California at San Diego, San Diego, CA., Bilen MA; Emory University Winship Cancer Institute, Atlanta, GA., Srinivas S; Stanford Cancer Center, Stanford, CA., Burgess EF; Levine Cancer Center, Charlotte, NC., Ramamurthy C; University of Texas Health Sciences Center at San Antonio, San Antonio, TX., George S; Roswell Park Cancer Center, Buffalo, NY., Geynisman DM; Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA., Bracarda S; Azienda Ospedaliera Santa Maria di Terni, Terni, Italy., Borchiellini D; Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France., Geoffrois L; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France., Maroto Rey JP; Hospital de la Santa Creu i Sant Paul, Barcelona, Spain., Ferrario C; Jewish General Hospital, Montreal, Quebec, Canada., Carret AS; Seagen Inc, Bothell, WA., Yu Y; Seagen Inc, Bothell, WA., Guseva M; Astellas Pharma, Northbrook, IL., Homet Moreno B; Merck & Co Inc, Rahway, NJ., Rosenberg JE; Memorial Sloan Kettering Cancer Center, New York, NY.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Sep 01; Vol. 41 (25), pp. 4107-4117. Date of Electronic Publication: 2023 Jun 27.

نوع المنشور: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Cisplatin*/adverse effects , Carcinoma, Transitional Cell*, Humans ; Antibodies, Monoclonal, Humanized/therapeutic use